The FDA’s approval of Novartis’s Kymirah and Gilead’s Yescarta has propelled cell-based therapies into the mainstream. However, manufacturing and characterizing these therapies at scale remains the next big challenge.
The Cell Therapy CMC and Manufacturing stream comprises two back-to-back conferences exploring the critical challenges facing the analysis and production of cell therapies with an emphasis on overcoming the practical challenges. Topics include international regulations, CMC strategies, characterization, automation in analytics and manufacturing, scaling up CRISPR-based CAR Ts, assay development, technology development and product release.
2018 CELL THERAPY TRACKS
Cell Therapy CMC and Analytics
Cell Therapy Manufacturing